NCT07484139: An ongoing trial by UNC Lineberger Comprehensive Cancer Center
This trial is ongoing. It must report results 3 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07484139 |
|---|---|
| Title | H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 30, 2026 |
| Completion date | May 31, 2028 |
| Required reporting date | May 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | May 22, 2026 |
| Days late | None |